Atriva Fast Tracks Antiviral Candidate As Coronavirus Arrives In Germany
Working With Doctors To Test Against Virus
Executive Summary
The antiviral specialist says MEK inhibitor could work against 2019-nCoV, but tests will take time.
You may also be interested in...
Codagenix-Serum Join Fray To Develop SARS-CoV-2 Vaccine
Codagenix, a company backed by Novartis, Merck and the Bill & Melinda Gates Foundation, has tied up with India’s Serum Institute to develop a vaccine against SARS-CoV-2, joining a heated race against the dreaded COVID-19 outbreak.
Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.
Vertex Joins Regulus In Kidney Disease Therapy Hunt
The Boston, MA biotech is about to enter the clinic with its autosomal dominant polycystic kidney disease candidate but microRNA therapy pioneer Regulus is already setting the pace.